 |
News releases
Please be advised that the information posted was accurate at the time of posting, but may be superseded by subsequent news releases.
To automatically receive future news releases, please go to the News
subscription service page.
2010
- 2009
- 2008
- 2007
- 2006
- [2005]
- 2004
- 2003
- 2002
(click to view the full text)
|
December 8, 2005
Æterna Zentaris subsidiary, Atrium Biotechnologies, acquires Douglas Laboratories in the U.S. |
November 21, 2005
Æterna Zentaris Announces Completion of Patient Enrollment for Ozarelix (D-63153) Phase II Trial in Benign Prostatic Hyperplasia |
November 21, 2005
Æterna Zentaris appoints a Board Vice Chairman, a New Chair of the Corporate Governance Committee, Two New Scientific Advisory Board Members and an IR Director |
November 15, 2005
Æterna Zentaris to Hold Investor and Analyst Day on November 21, 2005 in Toronto |
November 14, 2005
Æterna Zentaris Reports 2005 Third Quarter Financial and Operating Results |
November 9, 2005
Æterna Zentaris Announces 2005 Third Quarter Financial and Operating Results Conference Call and Webcast |
November 1, 2005
Æterna Zentaris to Present at Three Upcoming Investor Conferences in the United States and Europe |
October 13, 2005
Æterna Zentaris to Present at Upcoming Bio Investor Forum in San Francisco |
September 28, 2005
Æterna Zentaris to Present at Upcoming Bio Contact in Quebec City |
September 22, 2005
Æterna Zentaris Initiates Multi-Center Phase II trial of Perifosine in Combination with Radiotherapy in Non-Small Cell Lung Cancer |
September 21, 2005
Æterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York City |
September 15, 2005
Æterna Zentaris to Present at Upcoming CIBC World Markets Conference in Quebec City |
August 29, 2005
Æterna Zentaris Announces Completion of Patient Enrollment for Ozarelix (D 63153) Phase II Trial in Hormone-Dependent Prostate Cancer |
August 3, 2005
Æterna Zentaris Reports 2005 Second Quarter Financial and Operating Results |
July 27, 2005
Æterna Zentaris Announces 2005 Second Quarter Financial and Operating Results Conference Call and Webcast |
June 9, 2005
Æterna Zentaris to Present at BIO 2005 in Philadelphia |
May 31, 2005
Æterna Zentaris’ Partner Spectrum Granted IND from FDA to Conduct Phase I/II Clinical Trial with D-63153 in Hormone-Dependent Prostate Cancer in the United States |
May 26, 2005
Æterna Zentaris Holds Annual Shareholders’ Meeting
|
May 18, 2005
Æterna Zentaris to Hold Annual Shareholders Meeting on May 26 at the Ritz-Carlton Hotel in Montreal |
May 17, 2005
Æterna Zentaris: An Interim Report of Toxicity and Response From a US National Cancer Institute Phase III Trial in Lung Cancer with Neovastat |
May 16, 2005
Æterna Zentaris’ North American Partner Announces Disclosure of Phase II results with Perifosine in prostate cancer at the American Society of Clinical Oncology Annual (ASCO) Meeting |
May 11, 2005
Æterna Zentaris’ North American Partner Announces Upcoming Data Presentation on Perifosine at the American Society of Clinical Oncology Annual (ASCO) Meeting |
May 4, 2005
Æterna Zentaris Reports 2005 First Quarter Financial and Operating Results |
May 2, 2005
Æterna Zentaris Subsidiary Atrium Biotechnologies Reports First Quarter 2005 Financial and Operating Results |
April 27, 2005
Æterna Zentaris Announces 2005 First Quarter Financial and Operating Results Conference Call and Webcast |
April 21, 2005
Æterna Zentaris Expands Therapeutic Approaches in Oncology to Immunotherapeutic Vaccination |
April 19, 2005
Æterna Zentaris Announces Phase I Positive Results for its Oral Growth Hormone Secretagogue Compound EP-1572 |
April 14, 2005
Æterna Zentaris to Present Exciting New Data on Impavido® at the Third World Conference on Leishmaniasis |
April 13, 2005
Æterna Zentaris Announces Initiation of a European Multi Center Phase II Trial of D-63153 in Benign Prostate Hyperplasia |
April 11, 2005
Æterna Zentaris Announces Initiation of a European Multi-Center Phase II trial of D-63153 in Hormone-Dependent Prostate Cancer |
April 6, 2005
Æterna Zentaris Subsidiary Atrium Biotechnologies Completes Initial Public and Secondary Offering Totalling $75 Million |
April 5, 2005
Æterna Zentaris to Present at Three Upcoming Conferences in Europe |
March 30, 2005
Æterna Zentaris to Present at Upcoming CIBC World Markets Conference in New York City |
March 30, 2005
Æterna Zentaris Subsidiary Atrium Biotechnologies Files Final Prospectus for $75 Million Initial Public Offering |
March 23, 2005
Æterna Zentaris Receives First Regulatory Approval for Impavido® for Parasitic Skin Disease |
March 16, 2005
Æterna Zentaris Announces Decision to Continue Cetrorelix Development in Benign Prostate Hyperplasia in Japan |
March 16, 2005
Æterna Zentaris Announces Cetrorelix Development with Solvay Continues with Endometriosis as a Primary Indication |
February 28, 2005
Æterna Zentaris Reports 2004 Fourth Quarter and Full-Year
Financial and Operating Results
|
February 24, 2005
Appointments to Æterna Zentaris Scientific Advisory Board |
February 22, 2005
Æterna Zentaris Announces 2004 Fourth Quarter and Full Year Financial Results Conference Call and Webcast |
February 17, 2005
Æterna Zentaris Subsidiary Atrium Biotechnologies Files Preliminary Prospectus for Initial Public Offering |
February 14, 2005
Æterna Zentaris to Present at Upcoming Bio CEO and Wells Fargo Conferences in New York City |
January 25, 2005
Æterna Zentaris Subsidiary Atrium Biotechnologies Acquires Canadian Business Multichem |
January 18, 2005
Æterna Zentaris Advances AN-152 Targeted Anti-Cancer Agent into Clinical Development |
January 6, 2005
Æterna Zentaris Strengthens its Position in the Development of Innovative Signal Transduction Inhibitors as a Potential Way to Treat Cancer |
 |
 |
